Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis (BREEZE-AD2)

I4V-MC-JAHM -

The purpose of this study is to evaluate the efficacy and safety of baricitinib as a single drug treatment in participants with moderate to severe atopic dermatitis (eczema).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Atopic Dermatitis
What the trial is testing?
Baricitinib
Could I receive a Placebo?
Yes
Enrollment Goal
615
Trial Dates
Nov 27, 2017 - Dec 12, 2018
How long will I be in the trial?
Your participation could last up to 25 weeks and include up to 9 visits to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.